Strategic partnerships Basilea is actively pursuing collaborations to advance antimicrobials from AI-driven discovery to clinical trials, including recent partnerships with Phare Bio and Prokaryotics, presenting opportunities for co-development, joint funding, and expanded contribute-to-market initiatives.

Infectious disease focus With a portfolio centered on invasive fungal and severe bacterial infections and ongoing development of novel broad-spectrum antifungals and antibacterials, there is a clear venue for hospital formulary discussions, new indication outreach, and payer/uptake strategies targeting high-need patient populations.

Public funding leverage Active engagement in BARDA-partnered programs signals readiness to explore government- backed funding and milestone-driven programs, offering a path to co-financed trials, accelerated development, and potential milestone-based revenue streams.

Clinical-ready assets Recent launches of hospital brands Cresemba and Zevtera demonstrate Basilea’s commercialization experience and hospital-channel execution, suggesting sales collaboration opportunities for late-stage antifungal and antibacterial products, including market access and KOL engagement.

AI-enabled discovery Strategic use of AI to identify novel antimicrobials (in collaboration with Phare Bio) highlights a technology-forward line that can attract co-development, data-sharing, and analytics partnerships to optimize clinical trial design and accelerate time-to-market.